Data Insights

Pemigatinib by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval

Pemigatinib is under clinical development by Incyte and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Non-Small Cell Lung Cancer

Data Insights

Pemigatinib by Incyte for Breast Cancer: Likelihood of Approval

Pemigatinib is under clinical development by Incyte and currently in Phase II for Breast Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Breast Cancer

Data Insights

Pemigatinib by Incyte for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval

Pemigatinib is under clinical development by Incyte and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial...

Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Data Insights

Pemigatinib by Incyte for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Pemigatinib is under clinical development by Incyte and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Squamous Non-Small Cell Lung Cancer